NextCell Pharma publishes Interim Report 1 2020/2021

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans. For more information regarding the clinical trial, please see press release from 15th of September. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2017.

For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from the umbilical cord. Cellaviva is Sweden's first and only biobank for family-saving of stem cells and is owned by the stem cell company NextCell Pharma AB (NEXTCL). The applications for stem cell therapy are rapidly growing in modern medicine. Cells from family members are preferred for the treatment

NextCell Pharma AB ("NextCell") today announces that the company has been granted license for wholesale of cell based investigational medicinal products. The company was inspected earlier this summer by the Swedish Medical Products Agency. The permission is required for NextCell to acquire, stock and distribute investigational drugs in the planned clinical trial of ProTrans™ for treatment of diabetes. CEO Mathias Svahn says “This license is a good next step towards the start of our first clinical trial with ProTrans™ for the treatment of patients with Type 1 diabetes”. About the clinical

NextCell Pharma AB (NEXTCL) today announced that the company has responded to the Medicinal Product Agency's request for completion regarding the application for clinical trial with ProTrans ™. The study is designed to evaluate safety and efficacy in the treatment of type 1 diabetes. NextCell’s application was registered with the Medical Products Agency on July 24th and request for supplementary information was received on September 5th. This has now been submitted within the deadline of September 14th. The study is divided into two parts: The first part is a three-step dose escalation

NextCell Pharma AB (NEXTCL) announced today that the clinical trial application for ProTrans™ has been granted by the Ehtics Committee. ProTrans™ is a stem cell product developed with NextCell's Proprietary Selection Algorithm. The clinical trial is designed to evaluate the safety and efficacy of ProTrans™ for treatment of patients with type 1 diabetes. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska Trial Alliance (KTA), which

NextCell Pharma AB (”NextCell”) informs that during the next two weeks there is ample opportunities for (potential) investors to attend presentations given by and conduct discussions with NextCell Pharma personnel. Sessions where NextCell Pharma representatives will be present: · Aktiespararna Södertälje – September 4th 18:30-21:00 · Advanced Medicinal Therapy Products  – A game changer in medicine? – Malmoe, September 12th 13:00-17:00 · Nordic Life Science days, Malmoe  – September 12th – 14th · Aktiespararna Burlöv – September 13th 19:00-21:00 During these meetings

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM.

NextCell Pharma AB (NEXTCL) announced today that approval has been obtained from the Ethics Testing Board EPN, to develop assays from umbilical cord tissue. The collection is performed by regular staff at the clinic at Karolinska University Hospital in Huddinge. The project is conducted by Edvard Smith, Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet, and one of the founders of the Company. The results may be included in the Company's proprietary intellectual property regarding ProTrans. ProTrans is developed for stem cell therapies for